[Re-Engagement of Patients with Hepatitis C in the Context of COVID-19]
Related Experiment Video
Updated: Jan 9, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Gisela Fabiana Sotera1, Melina Ferreiro1, Margarita Martes1
1Hospital de Clínicas "José de San Martín". Universidad de Buenos Aires. Ciudad Autónoma de Buenos Aires, Argentina. Universidad de Buenos Aires Argentina.
Insights
Hepatitis C virus (HCV) infection poses a global health burden. A new program in Argentina simplifies patient care to improve diagnosis and treatment access, especially post-COVID-19.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Abstract:
Hepatitis C virus infection is one of the main causes of morbidity and mortality worldwide. In Argentina, it is estimated that only 50% of infected people are diagnosed; of these, half have confirmed their diagnosis, and only 5% have access to treatment. The COVID-19 pandemic has exacerbated this situation, further decreasing access to treatment. In this context, we developed a program to reconnect and simplify the patient care cascade, in order to facilitate access to diagnosis, treatment, and monitoring of complications associated with hepatitis C virus infection.
Related Concept Videos
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Myocarditis III: Medical Management
Retrovirus Life Cycles
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...

